Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
about
Modeling Kidney Disease with iPS CellsKey Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansCardiac and testicular toxicity effects of the latex and ethanolic leaf extract of Calotropis procera on male albino rats in comparison to abamectinHigh-content, high-throughput screening for the identification of cytotoxic compounds based on cell morphology and cell proliferation markersHigh-throughput imaging-based nephrotoxicity prediction for xenobiotics with diverse chemical structuresIn vitro cardiotoxicity assessment of environmental chemicals using an organotypic human induced pluripotent stem cell-derived model.Alzheimer's disease drug-development pipeline: few candidates, frequent failuresProfiling of toxicity and identification of distinct apoptosis profiles using a 384-well high-throughput flow cytometry screening platform.Network-based assessment of the selectivity of metabolic drug targets in Plasmodium falciparum with respect to human liver metabolismAssessing the translatability of in vivo cardiotoxicity mechanisms to in vitro models using causal reasoning.Combining computational methods for hit to lead optimization in Mycobacterium tuberculosis drug discovery.Precision toxicology based on single cell sequencing: an evolving trend in toxicological evaluations and mechanism exploration.A human liver microphysiology platform for investigating physiology, drug safety, and disease modelsProtective effect of pioglitazone on cardiomyocyte apoptosis in low-dose streptozotocin & high-fat diet-induced type-2 diabetes in ratsIn vitro screening for population variability in toxicity of pesticide-containing mixturesCellular and molecular studies of the effects of a selective COX-2 inhibitor celecoxib in the cardiac cell line H9c2 and their correlation with death mechanisms.3D Proximal Tubule Tissues Recapitulate Key Aspects of Renal Physiology to Enable Nephrotoxicity Testing.Investigative safety science as a competitive advantage for Pharma.Cell- and biomarker-based assays for predicting nephrotoxicity.High-content imaging-based BAC-GFP toxicity pathway reporters to assess chemical adversity liabilities.A multi-parameter in vitro screen in human stem cell-derived cardiomyocytes identifies ponatinib-induced structural and functional cardiac toxicity.From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.Engineering kidney cells: reprogramming and directed differentiation to renal tissues.Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.An impedance-based cellular assay using human iPSC-derived cardiomyocytes to quantify modulators of cardiac contractility.Regulatory Forum Opinion Piece: Carcinogen Risk Assessment: The Move from Screens to Science.Synthesis and Determination of Lipophilicity, Anticonvulsant Activity, and Preliminary Safety of 3-Substituted and 3-Unsubstituted N-[(4-Arylpiperazin-1-yl)alkyl]pyrrolidine-2,5-dione Derivatives.Deployment of in silico and in vitro safety assays in early-stage drug discovery.Hydroxybenzoic Acid Derivatives as Dual-Target Ligands: Mitochondriotropic Antioxidants and Cholinesterase Inhibitors.Building predictive in vitro pulmonary toxicity assays using high-throughput imaging and artificial intelligence.Compound-Specific Toxicities Detected in CFU-GM, Rat Kidney NRK Cells, Rat Bladder RBLAK Cells, and Rat Liver Slices following Batracylin or N-Acetyl Batracylin Exposure
P2860
Q26770384-33F06458-3898-4AE3-A088-91D8C1D3C811Q28075991-A2529BD4-EE89-49B8-894D-8F7CF4EF98A9Q28389917-C3806B49-F974-41AC-88F6-93D3F5E8E53AQ28539567-61DE2959-2D61-4A6A-84F4-37EDA2D8AD97Q28821950-674635E5-0720-4A8D-9857-B026EC27DC35Q32181083-20A6BE6F-0F35-4BF8-A913-4497DE4629F0Q33892815-3F929B9F-27B2-4B1E-B2FF-101D23310C42Q34229423-4E87097E-2ABB-4159-A0E7-40FC59779856Q34399911-72983C59-A699-4AA7-B53D-89AE7D68426FQ34980120-1933716A-5EB9-4CCB-B608-16831CCB5123Q35019457-BE305E6A-539E-471B-AD30-C524C27F1001Q36357450-760FAEF6-ADA9-419A-A875-0C3AF58E6B73Q36491320-FA436CD0-1E9F-4A04-AAD8-C46515119C33Q36550203-CA2CE130-49F0-44D3-8EFD-3720EC992DDFQ36636532-D84755FA-D0FE-40ED-8754-3C451C29292FQ37600036-918C3EE5-366D-4FCE-A007-E4132ED3C014Q37685354-27437AB6-CE46-49BF-927B-65DCDC10414DQ38024403-8C287263-5A90-4AEB-AC46-A61F2457F95CQ38266417-206A8E13-636D-4C73-A079-8911350F9054Q38846931-A97EBE32-F4A0-4E35-B4C7-225668A58786Q38949052-9DBF8243-0AD5-4410-9E8F-E07E3D63810EQ39030459-3204C406-6E57-4731-9F3B-F9BE271C82FBQ39339921-A66251E3-D77C-4CC0-B358-80A07E7B419AQ39366146-D8AD3B2F-2632-44BB-AE97-8E3A3B4B9D97Q46145054-A05BB4A7-3078-4166-A0E5-75022B4AB392Q46681240-F3AA84B8-A51B-4387-8BC8-0B3914B23613Q47633070-0E5E9CF0-4B95-4D80-AC0B-079CC6628DD6Q51577039-07EA99B9-69E0-4555-A993-BA722087797DQ55007733-6EFA0A79-2A9E-43BD-B0DD-94C55431E50EQ55347900-65A21D5D-879F-4B93-B0FB-193BF60F3B55Q59049303-DCBEF034-A6D5-41DE-A43A-0B2FF77134C8
P2860
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh
2011年學術文章
@zh-hant
name
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
@en
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
@nl
type
label
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
@en
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
@nl
prefLabel
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
@en
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
@nl
P356
P1476
Evaluation of drugs with specific organ toxicities in organ-specific cell lines.
@en
P2093
Yvonne Will
P304
P356
10.1093/TOXSCI/KFR339
P577
2011-12-13T00:00:00Z